Weight Loss
Personal Trainers Say Their Jobs Are Changing Due to the Rise of GLP-1s
NASM's new survey of 500 fitness pros shows GLP-1 drugs like Ozempic are reshaping the industry and the role of personal trainers.
Wearables Uncover Hidden Insights Into Overeating in New Study
A necklace, wristband and bodycam helped researchers reveal five hidden overeating styles that could shape the future of obesity treatment.
Rebel Wilson, Noom Partner as GLP-1s Enter Microdose Era
Rebel Wilson joins Noom as chief wellness ambassador, backing its new free tier that gamifies healthy habits and spotlights microdose GLP-1s.
Apple Fitness+ Partners With GLP-1 Provider FuturHealth
FuturHealth, a provider of weight-loss solutions including GLP-1s, will offer Apple Fitness+ at no additional cost to its members.
GLP-1s Opened the Door, Hims & Hers Says Personalization Holds the Key
Hims & Hers' Dr. Craig Primack explains why personalized care, not just GLP-1s, is the key to lasting weight loss success.
Syntis Bio Secures $38M for Weight Loss Pill That Mimics Gastric Bypass Surgery
Syntis Bio has raised $38M to advance its injectable-free, once-daily pill that mimics gastric bypass surgery.
Millions Rely on Fitness Trackers. A New Study Shows They’re Failing a Key Group
Northwestern researchers developed an open-source algorithm that improves fitness tracker accuracy for people with obesity.
Veracity Raises $6M to Scale Natural Metabolic Health Solutions
Veracity secures $6M from Maveron and Melitas Ventures to grow its metabolic health platform, including its best-selling Metabolism Ignite.
Modest Weight Loss in Midlife Can Slash Risk of Disease & Early Death, per Study
New research from links modest, nonpharmacological weight loss in midlife to lower long-term risks of chronic disease and early death.
Hims & Hers Joins Forces With Novo Nordisk
Hims & Hers and Novo Nordisk are teaming to expand affordable access to weight loss treatments, launching a bundled Wegovy offering.
